5.94

2.41% 0.14

Pre-market: 6.06 0.12 +2.02%

Edesa Biotech Inc (EDSA)

Overview News Price History Financials Discussions Forecast Stock Split

Edesa Biotech Inc stock is traded at $5.94, with a volume of 185.88K. It is up +2.41% in the last 24 hours and down -54.48% over the past month. Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Previous Close:

$5.80

Open:

$5.95

24h Volume:

185.88K

Relative Volume:

0.24

Market Cap:

$52.82M

Revenue:

Net Income/Loss:

$-7.82M

P/E Ratio:

-5.181

EPS:

-1.1465

Net Cash Flow:

$-8.00M

1W Performance:

+10.61%

1M Performance:

-54.48%

6M Performance:

+306.85%

1Y Performance:

+209.38%

1-Day Range:

$5.55

$6.23

1-Week Range:

$4.56

$6.27

52-Week Range:

$0.72

$20.32

Edesa Biotech Inc Stock (EDSA) Company Profile

Name

Edesa Biotech Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

(905) 475-1234

Address

100 SPY COURT, MARKHAM, ON

Employee

Twitter

@EdesaBiotech

Next Earnings Date

2026-05-13

Latest SEC Filings

EDSA's Discussions on Twitter

Compare EDSA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EDSA Edesa Biotech Inc	5.94	52.82M	0	-7.82M	-8.00M	-1.1465
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Edesa Biotech Inc Stock (EDSA) Latest News

Jun 15, 2026

Edesa Biotech Inc. Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Commercial R&D Costs PersistMargin Compression Risk - newsline.com

Jun 15, 2026

EDSA Q1 2026 Earnings: Misses EPS Estimates Amid Pre-Revenue Stage, Stock Rises 2.65%Mid-Term Outlook - newsline.com

Jun 15, 2026

Jun 13, 2026

Edesa Biotech Raises $3.5 Million in Private Placement, Issues 729,241 Shares - TradingView

Jun 11, 2026

Edesa Biotech (Nasdaq: EDSA) sets $3.5M PIPE led by CEO - Stock Titan

Jun 11, 2026

CEO backs $3.5M raise to advance Edesa vitiligo work - Stock Titan

Jun 11, 2026

Jun 09, 2026

Edesa Biotech, Inc. announced that it expects to receive $3.42014 million in funding - marketscreener.com

Jun 09, 2026

Edesa Biotech Company Profile & Introduction - Moomoo

Jun 09, 2026

Jun 08, 2026

EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech? - Stocktwits

Jun 08, 2026

Jun 05, 2026

Edesa reports exploratory data on AKI treatment candidate - Investing.com UK

Jun 05, 2026

Edesa reports exploratory data on AKI treatment candidate By Investing.com - Investing.com South Africa

Jun 05, 2026

Edesa Biotech Says Paridiprubart Linked to Lower Risk of Death in Acute Kidney Injury Patients - marketscreener.com

Jun 05, 2026

Exploratory AKI data show lower mortality with paridiprubart at Edesa (NASDAQ: EDSA) - Stock Titan

Jun 05, 2026

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury - GlobeNewswire

Jun 05, 2026

Jun 03, 2026

Acute Respiratory Distress Syndrome Market to Grow Steadily at a 3.8% CAGR Through 2036, Supported by Emerging ARDS Therapies | DelveInsight - GlobeNewswire Inc.

Jun 03, 2026

Jun 01, 2026

Edesa Biotech (NASDAQ: EDSA) CEO receives 1,671 restricted share units - Stock Titan

Jun 01, 2026

May 30, 2026

Edesa Biotech Shareholders Approve Directors and Compensation Plans - The Globe and Mail

May 30, 2026

May 29, 2026

Edesa Biotech (EDSA) director receives 19,000 restricted share units - Stock Titan

May 29, 2026

Edesa Biotech (EDSA) director granted 19,000 restricted share units - Stock Titan

May 29, 2026

Edesa Biotech (EDSA) director receives 19,000-share RSU award vesting over 12 months - Stock Titan

May 29, 2026

Edesa Biotech (EDSA) CFO receives 64,609 restricted share units under 2019 plan - Stock Titan

May 29, 2026

Edesa Biotech (EDSA) president awarded 64,609 restricted share units - Stock Titan

May 29, 2026

Edesa Biotech (EDSA) director receives 19,000-share equity grant, holds 30,000 - Stock Titan

May 29, 2026

[Form 4] Edesa Biotech, Inc. Insider Trading Activity - Stock Titan

May 29, 2026

Edesa Biotech (EDSA) director Da David Liu receives 19,000-share equity grant - Stock Titan

May 29, 2026

Edesa Biotech (NASDAQ: EDSA) boosts equity plan and reelects full board - Stock Titan

May 29, 2026

May 27, 2026

EDSA - Finviz

May 27, 2026

May 22, 2026